Genetic Variations in Cytochromes Affect
More than 85% of patients have significant genetic variations in the most important cytochromes – CYP2D6, CYP2C9, CYP2C19, CYP3A4 and CYP3A5. For example, CYP3A4 and CYP3A5 affect the metabolism of one-half of the drugs in clinical use, and this variance is profoundly affected based on patient ethnicity.
Genelex powered by the YouScript Precision Prescribing System tests these cytochromes (CYPs), which are responsible for metabolizing most commonly prescribed medications. Once tested, each patient is classified as a Poor, Intermediate, Normal, Rapid, or Ultra-rapid Metabolizer. These classifications describe a patient’s inherent drug metabolizing capacity, a major contributor to adverse drug events.
|Gene||Poor Metabolizer||Intermediate Metabolizer||Normal Metabolizer||Rapid or Ultrarapid Metabolizer|
*CYP2C19 variability depends on ethnicity.
The chart below describes effects that may be seen in patients with each of these phenotypes.
Until recently, you had little choice but to try medications without knowing in advance how patients might genetically respond. But no more: with precision prescribing by YouScript, you’ll know upfront what medications will likely prove the most effective for your patient – and which ones will not. And you’ll know how medications will interact with the prescriptions and supplements she’s already taking.